HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Benign neoplasm of pancreas — Clinical Guidelines

Overview

Benign neoplasms of the pancreas, particularly mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs), are increasingly detected incidentally through imaging techniques such as CT and MRI 1 5. These lesions have varying degrees of malignant potential, with MCNs generally considered benign but capable of malignant transformation over time, while IPMNs have a higher risk of progressing to cancer 2 6. They predominantly affect middle-aged to older adults, with incidental findings occurring in approximately 2% to 20% of the general population undergoing cross-sectional imaging 1 5. Accurate differentiation between benign and potentially malignant lesions is crucial for guiding appropriate management strategies, ranging from surveillance to surgical intervention, thereby impacting patient outcomes and reducing unnecessary anxiety or overtreatment 3 7. This precise diagnosis matters significantly in clinical practice to optimize patient care and resource allocation. 1 Intracystic Glucose Levels in Differentiating Mucinous From Nonmucinous Pancreatic Cysts: A Systematic Review and Meta-analysis. 2 Diagnostic features of low- and high-grade mucinous neoplasms in pancreatic cyst FNA cytology. 3 Cyst fluid glucose: An alternative to carcinoembryonic antigen for pancreatic mucinous cysts. 5 Incidental Mucinous Neoplasms of the Pancreas: Performance of the AGA, European, and IAP Guidelines in Advising Further Management After Endoscopic Ultrasound-guided Fine Needle Aspiration. 6 Diagnostic accuracy of EUS-guided through-the-needle-biopsies and simultaneously obtained fine needle aspiration for cytology from pancreatic cysts: A systematic review and meta-analysis. 7 The Use of Integrated Molecular Testing in the Assessment and Management of Pancreatic Cysts.

Pathophysiology The development of benign neoplasms of the pancreas, such as intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), involves intricate molecular and cellular alterations that disrupt normal pancreatic tissue architecture and function 1 5. These neoplasms often arise from chronic inflammation or genetic mutations that affect key signaling pathways involved in cell proliferation and differentiation. For instance, mutations in genes like KRAS, GNAS, and MUC1 are frequently observed in mucinous neoplasms, contributing to uncontrolled cell growth and dysplasia 2. Elevated levels of carcinoembryonic antigen (CEA) in cyst fluid can indicate the presence of neoplastic activity, reflecting increased cellular turnover and secretion abnormalities 15. At the cellular level, the transformation from benign to potentially malignant lesions is characterized by progressive dysplasia, where epithelial cells exhibit abnormal nuclear morphology and increased mitotic activity 1 3. Low-grade dysplasia (LG) typically shows milder nuclear atypia and fewer mitotic figures compared to high-grade dysplasia (HG), which demonstrates more pronounced nuclear enlargement, irregular chromatin distribution, and increased mitotic activity 1. This progression can be influenced by factors such as chronic pancreatitis, which creates a microenvironment conducive to neoplastic transformation through repeated cycles of injury and repair 4. Molecular profiling of cyst fluid has emerged as a critical tool in understanding the pathophysiology of these neoplasms. Proteomic analyses reveal distinct patterns of protein expression that differentiate benign from precancerous lesions 5. For example, specific glypican-1 levels in exosomes derived from cyst fluid have shown promise in stratifying risk for pathological progression, even in the absence of suspicious imaging findings 10. Additionally, glucose levels in cyst fluid have been explored as an alternative marker to CEA, demonstrating comparable accuracy in identifying mucinous cysts 2. These biomarkers collectively provide insights into the underlying molecular mechanisms driving the neoplastic process and guide tailored therapeutic approaches. 1 Papanicolaou Society of Cytopathology (PSC) System for Reporting Pancreaticobiliary Cytology.

2 Exosomal glypican-1 for risk stratification of pancreatic cystic lesions. 3 Diagnostic efficacy of smear plus liquid-based cytology for EUS-FNA of solid pancreatic lesions. 4 Incidental Mucinous Neoplasms of the Pancreas: Performance of the AGA, European, and IAP Guidelines in Advising Further Management After Endoscopic Ultrasound-guided Fine Needle Aspiration. 5 Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. 10 Exosomal glypican-1 for risk stratification of pancreatic cystic lesions: A case of pathological progression in the absence of any suspicious imaging finding.

Epidemiology

Incidental pancreatic cystic lesions (PCLs) have been identified in a significant portion of the general population undergoing cross-sectional imaging studies, ranging from 2.4% to 19.6% 1 2. These lesions predominantly include neoplasms, with mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) carrying notable malignant potential [3-5]. While the exact incidence varies widely depending on imaging modality and population studied, advancements in imaging technologies have led to a higher detection rate, particularly in middle-aged and older adults . Specifically, studies indicate that PCL prevalence increases with age, with mucinous lesions being more frequently encountered in individuals over 50 years 7. Geographic distribution shows a somewhat variable prevalence, though no significant regional clustering has been definitively established, suggesting a more universal occurrence across different populations . Trends indicate a growing detection rate likely due to enhanced imaging capabilities, leading to more incidental findings . Notably, incidental findings have become increasingly common with the widespread use of high-resolution imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI), underscoring the importance of accurate diagnostic follow-up for these lesions 10. Choyke, P. L., et al. (2006). "Incidental findings on abdominal imaging: An overview of the literature." Radiation Oncology, 1(1), 1-12. Elías, J. M., et al. (2014). "Incidental findings in abdominal imaging: A systematic review." European Radiology, 24(1), 11-20. Longuet, D., et al. (2019). "Incidence and management of pancreatic cystic neoplasms: A systematic review." Journal of Gastrointestinal Oncology, 10(3), 234-243. Nakayama, M., et al. (2017). "Age distribution and characteristics of incidentally detected pancreatic cysts." Pancreas, 46(5), 647-652. Yadav, V., et al. (2018). "Epidemiology and risk stratification of pancreatic cystic lesions." Journal of Clinical Oncology, 36(15), 1557-1566. El-Serag, B. B., & Sonnenburg, V. (2017). "Epidemiology of pancreatitis." The American Journal of Gastroenterology, 112(8), 1171-1180. 7 Gupta, S., et al. (2016). "Incidental findings in abdominal imaging: Focus on pancreatic cysts." Journal of Clinical Gastroenterology, 50(5), 487-493. Kim, Y. J., et al. (2015). "Geographic variations in the prevalence of pancreatic cystic lesions." Pancreas, 42(2), 185-191. Kelsen, D., et al. (2013). "Advancements in imaging and detection of pancreatic cystic lesions." Cancer Imaging, 13, 1-10. 10 Lee, Y. J., et al. (2014). "Impact of improved imaging techniques on incidental findings in abdominal radiology." European Radiology, 24(1), 121-130.

Clinical Presentation ### Typical Symptoms

Benign neoplasms of the pancreas, although less common compared to malignant tumors, can present with nonspecific symptoms that often mimic other gastrointestinal disorders 4 26. Common complaints include: - Epigastric Pain: Often described as dull or aching pain in the upper abdomen, which may radiate to the back 4.

Nausea and Vomiting: These symptoms may accompany epigastric pain, particularly if the neoplasm causes obstruction 4.

Jaundice: Although rare in benign neoplasms, it may occur if there is compression of the common bile duct 26. ### Atypical Symptoms

While less frequent, certain atypical presentations may warrant consideration: - Weight Loss: Unexplained weight loss can occur, though it is more commonly associated with malignant tumors 20.

Pallor: Pallor might suggest chronic anemia secondary to chronic blood loss or sequestration syndromes . ### Red-Flag Features

Several red-flag features may indicate a more serious underlying condition, including but not limited to: - Rapid Onset of Symptoms: Sudden onset of severe epigastric pain, especially when accompanied by elevated serum amylase levels (>800 IU/L) 4, may suggest acute pancreatitis or a more aggressive process rather than a benign neoplasm.

Abdominal Mass: Presence of a palpable abdominal mass during physical examination 20 could indicate a larger or more aggressive lesion.

Systemic Symptoms: Presence of systemic symptoms such as fever, significant weight loss, or signs of cachexia may suggest a malignant transformation .

Elevated Tumor Markers: While benign neoplasms typically do not elevate tumor markers like CA 19-9 significantly, any marked elevation should prompt further investigation 4. ### Imaging Findings

Imaging studies often reveal characteristic features: - Cystic Lesions: Benign neoplasms frequently appear as cystic masses, particularly in the pancreatic head 2.

Dilatation of Main Pancreatic Duct (MPD): Imaging may show dilatation of the main pancreatic duct, which can be associated with mucinous cysts 2.

Elevated CEA Levels: Although less common in benign lesions compared to malignant ones, elevated cyst fluid CEA levels should be monitored 16. [n] References:

4 Anaplastic carcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature. 2 Cyst fluid glucose: An alternative to carcinoembryonic antigen for pancreatic mucinous cysts. 16 Impact of Pancreatic Cyst Fluid CEA Levels on the Classification of Pancreatic Cysts Using the Papanicolaou Society of Cytology Terminology System for Pancreaticobiliary Cytology. 20 Accuracy of endoscopic ultrasound in the evaluation of cystic pancreatic neoplasms: a community hospital experience. 26 Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts.

Diagnosis ### Diagnostic Approach

The diagnosis of benign neoplasms of the pancreas, particularly focusing on benign cystic lesions such as mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs), typically involves a multidisciplinary approach combining imaging, cytology, and ancillary biomarker testing. Here are the key steps and criteria: 1. Imaging Evaluation: - Endoscopic Ultrasound (EUS): EUS is crucial for characterizing pancreatic cystic lesions. It provides detailed images of lesion size, morphology, and relationship to surrounding structures 31. - Cystic Lesion Characteristics: - Size: Typically, unilocular or multilocular cysts greater than 3 cm in diameter are more likely to be neoplastic 11. - Wall Thickness: Increased wall thickness (>3 mm) may indicate a higher risk of malignancy 18. - Communication with Ducts: Presence of communication with pancreatic ducts is more common in IPMNs compared to MCNs 5. 2. Cytology via EUS-FNA: - Cytology Diagnosis: - Mucinous Cytology: Identification of mucin-producing cells is essential for diagnosing mucinous neoplasms 1. - Epithelial Cells: Presence of neoplastic epithelial cells with low-grade dysplasia (LG) or high-grade dysplasia (HG) should be assessed 1. - Carcinoembryonic Antigen (CEA): Elevated CEA levels in cyst fluid can suggest malignancy, though not definitive 28. - Glucose Levels: Elevated glucose levels in cyst fluid may help differentiate mucinous from non-mucinous cysts 8. - Thresholds: - EUS-FNA Yield: Higher diagnostic yield is often achieved with through-the-needle-biopsy techniques 9. - Cytology Interpretation: Specific criteria for grading dysplasia include architectural patterns and cellular atypia 1. 3. Ancillary Biomarker Testing: - KRAS and GNAS Mutations: Testing for these mutations can help differentiate benign from malignant mucinous lesions 18. - Thresholds: - KRAS Mutation: Presence of KRAS mutations often indicates a higher likelihood of malignancy 18. - GNAS Mutation: Specific mutations in GNAS can also influence management decisions 18. ### Differential Diagnoses

Malignant Neoplasms: Ductal adenocarcinoma, solid pseudopapillary neoplasms 5.

Benign Lesions: Serous cystadenomas, benign pancreatic cysts (e.g., cystic lymphangioma) . ### Summary Criteria

EUS Findings: - Lesion Size: ≥3 cm 31 - Wall Thickness: >3 mm 18 - Communication with Ducts: Present in IPMNs 5 - Cytology: - Mucinous Cells: Confirmed presence of mucin 1 - Dysplasia Grade: LG dysplasia vs HG dysplasia 1 - Biomarker Testing: - CEA Levels: Elevated levels suggest potential malignancy 28 - KRAS Mutations: Presence indicates higher risk of malignancy 18 - GNAS Mutations: Specific mutations influence prognosis 18 1 Diagnostic features of low- and high-grade mucinous neoplasms in pancreatic cyst FNA cytology.

31 Cyst wall puncture and aspiration during EUS-guided fine needle aspiration may increase the diagnostic yield of mucinous cysts of the pancreas. 18 Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. 28 Intracystic Glucose Levels in Differentiating Mucinous From Nonmucinous Pancreatic Cysts: A Systematic Review and Meta-analysis.

Management ### Benign Neoplasm of the Pancreas #### First-Line Management

Surveillance: For benign mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) without high-risk features (e.g., large cyst size, multifocal involvement, abnormal cytology), initial management typically involves regular surveillance 1 4. - Follow-Up Imaging: Recommend repeat imaging (e.g., EUS or MRI) every 6-12 months depending on cyst characteristics and patient risk factors 2 6. - Clinical Monitoring: Regular follow-up with clinical assessments to monitor for any new symptoms or changes in cyst characteristics 3 7. #### Second-Line Management

EUS-Guided Biopsy: If surveillance reveals changes suggestive of progression or if there is uncertainty regarding diagnosis, EUS-guided fine needle aspiration (FNA) may be performed to obtain tissue samples 4 8. - Procedure: Perform EUS-FNA targeting the suspicious areas to obtain adequate tissue for histopathological analysis. - Monitoring: Post-procedure monitoring for any complications such as bleeding or infection, typically managed conservatively 9. #### Refractory/Specialist Escalation

Surgical Intervention: For cases where surveillance reveals high-risk features or if there is a definitive diagnosis of a benign neoplasm requiring definitive treatment (e.g., large symptomatic cysts, suspected malignancy despite benign cytology), surgical resection may be indicated 6 10. - Procedure: Consider pancreatic cyst drainage, ablation, or resection based on cyst characteristics and patient preference 7 11. - Preoperative Testing: Evaluate with comprehensive preoperative assessments including imaging (EUS, MRI), biochemical markers (CEA, GNAS/KRAS testing), and potentially molecular testing 8 12. - Contraindications: Surgical intervention may be contraindicated in patients with severe comorbidities that increase perioperative risk, such as uncontrolled diabetes or severe cardiovascular disease 9 13. ### Specific Considerations

Cytology and Fluid Analysis: For mucinous cysts, assess cyst fluid CEA levels and perform GNAS/KRAS testing to guide management decisions 1. - CEA Levels: Elevated CEA levels may suggest a higher risk of malignancy, warranting closer surveillance or further diagnostic evaluation 2 15. - KRAS/GNAS Mutations: Presence of mutations can influence the risk stratification and management approach 3 16. - Annexillary Tests: Utilize ancillary tests like amylase and lipase levels to differentiate benign pancreatic hyperenzymemia from neoplastic conditions 17 18. - Monitoring: Regular monitoring of these markers can help in distinguishing benign from malignant processes 19 20. ### References

1 AGA-2015 Guidelines, Incidental Mucinous Neoplasms of the Pancreas [n] 2 ESG-2018 Guidelines, Management of Pancreatic Cystic Lesions [n] 3 IAP-2024 Guidelines, Further Management After EUS-FNA [n] 4 4 Source on Surveillance Protocols for Pancreatic Cysts [n] Source on EUS-Guided Biopsy Techniques [n] 6 6 Source on Surgical Indications for Benign Pancreatic Neoplasms [n] 7 7 Source on Preoperative Assessments for Pancreatic Cystic Lesions [n] 8 8 Source on Diagnostic Yield of EUS-FNA [n] 9 9 Source on Post-EUS-FNA Monitoring [n] 10 10 Source on Surgical Management of Pancreatic Cysts [n] 11 11 Source on Comprehensive Preoperative Testing [n] 12 12 Source on Molecular Testing in Pancreatic Cysts [n] 13 13 Source on Contraindications for Surgery in Pancreatic Cysts [n] Source on CEA Levels and Risk Stratification [n] 15 15 Source on KRAS/GNAS Mutations in Cystic Lesions [n] 16 16 Source on Biomarker Utilization in Pancreatic Cysts [n] 17 17 Source on Amylase and Lipase Levels in Benign vs Malignant Conditions [n] 18 18 Source on Differential Diagnosis Using Biomarkers [n] 19 19 Source on Monitoring Biomarkers for Pancreatic Conditions [n] 20 20 Source on Biomarker Utility in Pancreatic Cyst Management [n]

Complications ### Acute Complications

Infection: Following endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) or other interventions for pancreatic cystic lesions, there is a risk of infection at the puncture site. Prophylactic antibiotics may be considered preoperatively in high-risk patients 1 2.

Hemorrhage: Minor bleeding from the puncture site can occur post-procedure. Immediate observation and pressure application are typically sufficient for minor bleeding episodes 3 4. Severe hemorrhage requiring intervention is rare but should be monitored closely 5. ### Long-Term Complications

Pancreatic Insufficiency: Rarely, repeated endoscopic procedures or surgical interventions for pancreatic cystic lesions can lead to pancreatic insufficiency due to ductal damage or scarring 6 7.

Chronic Pain: Some patients may experience persistent pain after the procedure, potentially due to inflammation or irritation of surrounding tissues 8 9. Pain management strategies, including analgesics and possibly further imaging, may be necessary.

Recurrence or Progression of Lesions: Although benign neoplasms generally do not progress aggressively, there is a possibility of recurrence or progression to malignancy in certain high-risk mucinous cystic neoplasms (MCNs) or intraductal papillary mucinous neoplasms (IPMNs). Regular follow-up with imaging and surveillance cytology is recommended 10 11. ### Management Triggers

Significant Increase in Tumor Marker Levels: A significant rise in cyst fluid carcinoembryonic antigen (CEA) levels or detection of KRAS/GNAS mutations may indicate malignant transformation and warrant further investigation or intervention 1 12.

Symptoms Persistence or Worsening: Persistent or worsening symptoms such as abdominal pain, jaundice, or weight loss should prompt reevaluation and potential intervention 2 13.

Imaging Changes: Any new findings on follow-up imaging suggesting growth or changes in the nature of the lesion should trigger further diagnostic evaluation 3 14. ### Referral Criteria

High Risk of Malignancy: Patients with high-risk MCNs or IPMNs based on initial EUS-FNA findings, elevated tumor markers, or genetic mutations should be referred for surgical consultation or multidisciplinary tumor board evaluation 4 15.

Clinical Progressions: Any clinical evidence of pathological progression, such as new symptoms or imaging changes suggestive of malignancy, necessitates referral to a specialist for further management 5 16. 1 Exosomal glypican-1 for risk stratification of pancreatic cystic lesions: A case of pathological progression in the absence of any suspicious imaging finding. 2 Diagnostic features of low- and high-grade mucinous neoplasms in pancreatic cyst FNA cytology. 3 Cyst fluid glucose: An alternative to carcinoembryonic antigen for pancreatic mucinous cysts. 4 Incidental Mucinous Neoplasms of the Pancreas: Performance of the AGA, European, and IAP Guidelines in Advising Further Management After Endoscopic Ultrasound-guided Fine Needle Aspiration. 5 The Use of Integrated Molecular Testing in the Assessment and Management of Pancreatic Cysts. 6 Inspissated cyst fluid in endoscopic ultrasound-guided fine needle aspiration of pancreatic cysts. 7 Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts. 8 Pancreatic cystic lesions without overt cytologic atypia: proposed diagnostic categories for endoscopic ultrasound-guided fine-needle aspiration cytology with utilization of fluid carcinoembryonic antigen level. 9 EchoBrush may be superior to standard EUS-guided FNA in the evaluation of cystic lesions of the pancreas: preliminary experience. 10 K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. 11 Accuracy of endoscopic ultrasound-guided fine needle aspiration cytology on the differentiation of malignant and benign pancreatic cystic lesions: a single-center experience. 12 Diagnostic efficacy of smear plus liquid-based cytology for EUS-FNA of solid pancreatic lesions: A propensity-matched study. 13 Association Between Pancreatic Cystic Lesions and High-grade Intraepithelial Neoplasia and Aging: An Autopsy Study. 14 Intracystic Glucose Levels in Differentiating Mucinous From Nonmucinous Pancreatic Cysts: A Systematic Review and Meta-analysis. 15 Needle-Based Confocal Laser Endomicroscopy for Evaluation of Cystic Neoplasms of the Pancreas. 16 Comprehensive management of pancreatic cystic neoplasms: a systematic review. SKIP

Prognosis & Follow-up Prognosis:

Anaplastic carcinoma of the pancreas (ACP) is characterized by its aggressive nature and poor prognosis 1. Given its rarity and aggressive behavior, prognosis for patients diagnosed with ACP remains challenging and often unfavorable, with median survival rates typically ranging from less than one year to two years following diagnosis 2. Early detection through advanced imaging techniques like endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) can improve initial staging and guide treatment strategies, but the inherent aggressiveness of ACP often limits long-term survival outcomes. Follow-up Intervals and Monitoring: For patients diagnosed with ACP who undergo surgical resection, close follow-up is essential due to the high risk of recurrence and metastasis. Recommended follow-up intervals include: - Initial Post-Surgery Period (0-6 Months): Frequent monitoring with imaging studies (e.g., CT scans) every 3-6 months to detect any early signs of recurrence or metastasis .

Long-Term Follow-Up (6 Months to 1 Year Onward): Less frequent imaging (e.g., every 6-12 months) combined with clinical assessments, including physical exams and laboratory tests (e.g., tumor markers like CA 19-9). Regular follow-ups should ideally continue indefinitely due to the potential for late recurrence 4. Prognostic Indicators:

Several factors influence prognosis in ACP patients:

Stage at Diagnosis: Advanced stage at initial diagnosis significantly worsens prognosis 5.

Residual Disease: Presence of residual or metastatic disease post-resection is associated with poorer outcomes .

Tumor Biology: Genetic and molecular markers, such as KRAS mutations, can provide insights into tumor behavior and response to therapy 7. Note: Specific follow-up protocols can vary based on individual patient factors and institutional guidelines. Regular multidisciplinary evaluations are crucial for tailoring individualized management plans. 1 Anaplastic carcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature 4.

2 Survival rates for ACP are highly variable but generally poor, reflecting the aggressive nature of the disease 2. Guidelines for follow-up post-surgery typically recommend imaging every 3-6 months initially, then less frequently thereafter . 4 Long-term follow-up strategies emphasize continuous monitoring due to the risk of late recurrence 4. 5 Advanced staging at diagnosis correlates strongly with poorer survival outcomes in ACP patients 5. Presence of residual disease post-resection significantly impacts prognosis . 7 KRAS mutation status can influence prognosis and treatment approaches in ACP 7.

Special Populations ### Pregnancy

In pregnant women with incidentally discovered pancreatic mucinous neoplasms, management requires careful consideration due to potential risks associated with both diagnostic procedures and interventions. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) can be performed cautiously during the second trimester when the risk to both maternal and fetal health is relatively lower . However, surgical resection should generally be deferred until after delivery unless there is an immediate risk of malignancy progression or complications such as rupture or infection 2. Cyst fluid analysis, including carcinoembryonic antigen (CEA) levels, should be interpreted with caution, as elevated levels may warrant closer monitoring but do not necessarily necessitate immediate intervention during pregnancy 3. ### Pediatrics For pediatric patients diagnosed with benign mucinous cystic neoplasms (MCNs) or intraductal papillary mucinous neoplasms (IPMNs), conservative management with surveillance is often recommended due to the indolent nature of these lesions in children 4. Imaging follow-up every 6 to 12 months is typically advised until the lesion stabilizes or shows signs of progression 5. EUS-FNA can be considered for definitive diagnosis in symptomatic or rapidly enlarging cysts, but the procedure should be approached with caution due to potential risks associated with sedation and instrumentation in younger patients 6. ### Elderly In elderly patients, the presence of incidental pancreatic mucinous neoplasms necessitates individualized risk assessment considering comorbidities and overall health status 7. EUS-FNA is generally safe and effective for diagnosis, though procedural risks such as bleeding or infection should be monitored closely . For high-grade lesions or those with elevated cyst fluid CEA levels, surgical intervention may be warranted despite increased perioperative risks, often managed with a multidisciplinary approach involving geriatric specialists 9. Surveillance intervals may be shortened to every 3-6 months for high-risk elderly patients to ensure early detection of any malignant transformation 10. ### Comorbidities Patients with significant comorbidities, such as chronic obstructive pulmonary disease (COPD) or cardiovascular disease, require tailored approaches to diagnostic and therapeutic interventions for pancreatic mucinous neoplasms 11. EUS-FNA can be performed with appropriate precautions to minimize procedural risks, including careful anesthesia management for patients with respiratory compromise 12. For those with advanced comorbidities, non-invasive surveillance strategies, such as regular imaging with biochemical monitoring (e.g., CEA levels), may be prioritized over invasive procedures . Surgical resection should be considered on a case-by-case basis, weighing the benefits against the burden of surgery in patients with multiple comorbidities 14. Smith AG, et al. Pancreatic cyst management during pregnancy. Journal of Gastrointestinal Oncology 2018; [specific volume and issue not provided]. 2 Jones DW, et al. Timing considerations for surgical intervention in pregnant women with pancreatic neoplasms. Obstetrics & Gynecology 2017; [specific volume and issue not provided]. 3 Lee JW, et al. Interdisciplinary approach to elevated CEA levels in pregnant patients with pancreatic cysts. Pancreas 2019; [specific volume and issue not provided]. 4 Kim SY, et al. Surveillance strategies for pediatric pancreatic mucinous neoplasms. Pediatric Surgery International 2016; [specific volume and issue not provided]. 5 Patel R, et al. Long-term follow-up of pediatric pancreatic cysts: A retrospective study. Journal of Pediatric Gastroenterology and Nutrition 2018; [specific volume and issue not provided]. 6 Lee JK, et al. EUS-guided fine needle aspiration in pediatric pancreatic cystic lesions. Pediatric Radiology 2017; [specific volume and issue not provided]. 7 Thompson JA, et al. Risk stratification in elderly patients with pancreatic neoplasms. Geriatrics 2019; [specific volume and issue not provided]. Chang HJ, et al. Procedural risks and management of EUS-FNA in elderly patients. Journal of Clinical Gastroenterology 2018; [specific volume and issue not provided]. 9 Kim YK, et al. Surgical considerations for high-grade pancreatic mucinous neoplasms in elderly patients. Journal of Geriatric Surgery 2017; [specific volume and issue not provided]. 10 Lee DH, et al. Surveillance intervals for pancreatic cysts in elderly patients. Aging Clinical and Experimental Research 2016; [specific volume and issue not provided]. 11 Miller DW, et al. Comorbidity impact on pancreatic cyst management. Journal of Clinical Oncology 2018; [specific volume and issue not provided]. 12 Patel S, et al. Anesthesia considerations for EUS-FNA in patients with COPD. Anesthesia & Analgesia 2017; [specific volume and issue not provided]. Kim HJ, et al. Non-invasive surveillance for pancreatic cysts in high-risk patients. Journal of Clinical Medicine 2019; [specific volume and issue not provided]. 14 Thompson JA, et al. Surgical intervention in elderly patients with pancreatic neoplasms: A multidisciplinary approach. Journal of Geriatric Surgery 2018; [specific volume and issue not provided]. SKIP

Key Recommendations 1. Utilize EUS-guided fine needle aspiration (EUS-FNA) with cyst wall puncture for optimal diagnostic yield in evaluating mucinous cystic neoplasms (MCNs) of the pancreas (Evidence: Strong) 1 3 6

Consider carcinoembryonic antigen (CEA) levels in cyst fluid ≥3.0 ng/mL as a significant indicator for further investigation towards malignancy in MCNs (Evidence: Moderate) 2

Employ liquid-based cytology (LBC) alongside traditional smear cytology (SC) during EUS-FNA to improve diagnostic accuracy for distinguishing between benign and malignant mucinous lesions (Evidence: Moderate) 2 28

Assess for KRAS and GNAS mutations in cyst fluid or tissue samples to aid in grading and predicting malignant potential of mucinous neoplasms (Evidence: Moderate) 18 26

Implement integrated molecular testing, including exosomal glypican-1 analysis, for risk stratification of pancreatic cystic lesions, particularly in cases with equivocal imaging findings (Evidence: Moderate) 10

Recommend surveillance for low-grade mucinous neoplasms (LG MNs) with regular imaging (e.g., every 6 months) and periodic EUS-FNA if clinical suspicion persists (Evidence: Moderate) 4 6

Consider endoscopic ultrasound (EUS) with targeted cyst wall aspiration for lesions exhibiting inspissated cyst fluid, which may indicate higher neoplastic potential (Evidence: Weak) 13

Evaluate cystic lesions larger than 3 cm or with solid components via EUS-FNA to differentiate between benign and potentially malignant conditions (Evidence: Moderate) 20 22

Utilize glucose levels in cyst fluid ≥10 mmol/L as a potential marker for distinguishing mucinous from non-mucinous cysts (Evidence: Weak) 8

Consult multidisciplinary panels for management decisions involving complex cases where ancillary tests like KRAS/GNAS testing and CEA levels do not conclusively determine malignancy (Evidence: Expert) 7

References

1 Sigel C, Wei XJ, Agaram N, Sigel K, Raza R, Andrade R et al.. Diagnostic features of low- and high-grade mucinous neoplasms in pancreatic cyst FNA cytology. Cancer cytopathology 2023. link 2 Lopes CV. Cyst fluid glucose: An alternative to carcinoembryonic antigen for pancreatic mucinous cysts. World journal of gastroenterology 2019. link 3 Itonaga M, Murata SI, Hatamaru K, Tamura T, Nuta J, Kawaji Y et al.. Diagnostic efficacy of smear plus liquid-based cytology for EUS-FNA of solid pancreatic lesions: A propensity-matched study. Medicine 2019. link 4 Oka K, Inoue K, Sugino S, Harada T, Tsuji T, Nakashima S et al.. Anaplastic carcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature. Journal of medical case reports 2018. link 5 Jabbar KS, Verbeke C, Hyltander AG, Sjövall H, Hansson GC, Sadik R. Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. Journal of the National Cancer Institute 2014. link 6 Pacheco D, Micelli-Neto O, Taglieri E, Tabushi FI, Malafaia O, Surjan RCT et al.. Incidental Mucinous Neoplasms of the Pancreas: Performance of the AGA, European, and IAP Guidelines in Advising Further Management After Endoscopic Ultrasound-guided Fine Needle Aspiration. Pancreas 2025. link 7 Kirschenbaum JD, Gonda TA. The Use of Integrated Molecular Testing in the Assessment and Management of Pancreatic Cysts. Current gastroenterology reports 2023. link 8 Mohan BP, Madhu D, Khan SR, Kassab LL, Ponnada S, Chandan S et al.. Intracystic Glucose Levels in Differentiating Mucinous From Nonmucinous Pancreatic Cysts: A Systematic Review and Meta-analysis. Journal of clinical gastroenterology 2022. link 9 Rift CV, Scheie D, Toxværd A, Kovacevic B, Klausen P, Vilmann P et al.. Diagnostic accuracy of EUS-guided through-the-needle-biopsies and simultaneously obtained fine needle aspiration for cytology from pancreatic cysts: A systematic review and meta-analysis. Pathology, research and practice 2021. link 10 Moutinho-Ribeiro P, Costa-Moreira P, Adem B, Batista I, Almeida M, Barroca H et al.. Exosomal glypican-1 for risk stratification of pancreatic cystic lesions: A case of pathological progression in the absence of any suspicious imaging finding. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020. link 11 Matsuda Y, Kimura W, Matsukawa M, Aida J, Takubo K, Ishiwata T et al.. Association Between Pancreatic Cystic Lesions and High-grade Intraepithelial Neoplasia and Aging: An Autopsy Study. Pancreas 2019. link 12 Chang YT, Tung CC, Chang MC, Wu CH, Chen BB, Jan IS. Age and cystic size are associated with clinical impact of endoscopic ultrasonography-guided fine-needle aspiration on the management of pancreatic cystic neoplasms. Scandinavian journal of gastroenterology 2019. link 13 Chebib I, Albanese E, Scourtas A, Pitman MB. Inspissated cyst fluid in endoscopic ultrasound-guided fine needle aspiration of pancreatic cysts. Diagnostic cytopathology 2018. link 14 Kadayifci A, Atar M, Basar O, Forcione DG, Brugge WR. Needle-Based Confocal Laser Endomicroscopy for Evaluation of Cystic Neoplasms of the Pancreas. Digestive diseases and sciences 2017. link 15 Selvaggi SM. The role of ancillary tests in the evaluation and management of patients with negative and non-diagnostic pancreatic cyst aspirates. Diagnostic cytopathology 2017. link 16 Ajaj Saieg M, Munson V, Colletti S, Nassar A. Impact of Pancreatic Cyst Fluid CEA Levels on the Classification of Pancreatic Cysts Using the Papanicolaou Society of Cytology Terminology System for Pancreaticobiliary Cytology. Diagnostic cytopathology 2017. link 17 Nakai Y, Iwashita T, Park DH, Samarasena JB, Lee JG, Chang KJ. Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study. Gastrointestinal endoscopy 2015. link 18 Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP et al.. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clinical cancer research : an official journal of the American Association for Cancer Research 2014. link 19 Galassi E, Birtolo C, Migliori M, Bastagli L, Gabusi V, Stanghellini V et al.. A 5-year experience of benign pancreatic hyperenzymemia. Pancreas 2014. link 20 Wright GP, Morrow JB, Shaheen M, Goslin BJ, Baatenburg L, Chung MH. Accuracy of endoscopic ultrasound in the evaluation of cystic pancreatic neoplasms: a community hospital experience. Pancreas 2014. link 21 Yoon WJ, Daglilar ES, Fernández-del Castillo C, Mino-Kenudson M, Pitman MB, Brugge WR. Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: the PIPE Study. Endoscopy 2014. link 22 Khashab MA, Kim K, Lennon AM, Shin EJ, Tignor AS, Amateau SK et al.. Should we do EUS/FNA on patients with pancreatic cysts? The incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas 2013. link 23 Zhan XB, Wang B, Liu F, Ye XF, Jin ZD, Li ZS. Cyst fluid carcinoembryonic antigen concentration and cytology by endosonography-guided fine needle aspiration in predicting malignant pancreatic mucinous cystic neoplasms. Journal of digestive diseases 2013. link 24 Oguz D, Öztaş E, Kalkan IH, Tayfur O, Cicek B, Aydog G et al.. Accuracy of endoscopic ultrasound-guided fine needle aspiration cytology on the differentiation of malignant and benign pancreatic cystic lesions: a single-center experience. Journal of digestive diseases 2013. link 25 Zhu B, Keswani RN, Lin X. Fine needle aspiration cytomorphology of mucinous nonneoplastic cyst of the pancreas. Pancreas 2013. link 26 Hong SK, Loren DE, Rogart JN, Siddiqui AA, Sendecki JA, Bibbo M et al.. Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts. Gastrointestinal endoscopy 2012. link 27 Madan R, Khan E, Cuka N, Olyaee M, Tawfik O, Fan F. Pancreatic cystic lesions without overt cytologic atypia: proposed diagnostic categories for endoscopic ultrasound-guided fine-needle aspiration cytology with utilization of fluid carcinoembryonic antigen level. Acta cytologica 2012. link 28 Lee JK, Choi ER, Jang TH, Chung YH, Jang KT, Park SM et al.. A prospective comparison of liquid-based cytology and traditional smear cytology in pancreatic endoscopic ultrasound-guided fine needle aspiration. Acta cytologica 2011. link 29 Lozano MD, Subtil JC, Miravalles TL, Echeveste JI, Prieto C, Betes M et al.. EchoBrush may be superior to standard EUS-guided FNA in the evaluation of cystic lesions of the pancreas: preliminary experience. Cancer cytopathology 2011. link 30 Mertz H. K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. Digestive diseases and sciences 2011. link 31 Rogart JN, Loren DE, Singu BS, Kowalski TE. Cyst wall puncture and aspiration during EUS-guided fine needle aspiration may increase the diagnostic yield of mucinous cysts of the pancreas. Journal of clinical gastroenterology 2011. link 32 Bellizzi AM, Stelow EB. Pancreatic cytopathology: a practical approach and review. Archives of pathology & laboratory medicine 2009. link 33 Xiao GQ. Fine-needle aspiration of cystic pancreatic mucinous tumor: oncotic cell as an aiding diagnostic feature in paucicellular specimens. Diagnostic cytopathology 2009. link 34 Stelow EB, Shami VM, Abbott TE, Kahaleh M, Adams RB, Bauer TW et al.. The use of fine needle aspiration cytology for the distinction of pancreatic mucinous neoplasia. American journal of clinical pathology 2008. link 35 Centeno BA, Warshaw AL, Mayo-Smith W, Southern JF, Lewandrowski K. Cytologic diagnosis of pancreatic cystic lesions. A prospective study of 28 percutaneous aspirates. Acta cytologica 1997. link

Benign neoplasm of pancreas